Please use this identifier to cite or link to this item:
http://repository.kln.ac.lk/handle/123456789/18615
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mettananda, S. | |
dc.contributor.author | Higgs, D.R. | |
dc.date.accessioned | 2018-03-07T08:07:50Z | |
dc.date.available | 2018-03-07T08:07:50Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Hematology/oncology Clinics of North America.2018;32(2):177-191 | en_US |
dc.identifier.issn | 0889-8588 (Print) | |
dc.identifier.issn | 1558-1977 (Electronic) | |
dc.identifier.issn | 0889-8588 (Linking) | |
dc.identifier.uri | http://repository.kln.ac.lk/handle/123456789/18615 | |
dc.description | Indexed In MEDLINE | en_US |
dc.description.abstract | Thalassemia is a disorder of hemoglobin characterized by reduced or absent production of one of the globin chains in human red blood cells with relative excess of the other. Impaired synthesis of β-globin results in β-thalassemia, whereas defective synthesis of α-globin leads to α-thalassemia. Despite being a monogenic disorder, thalassemia exhibits remarkable clinical heterogeneity that is directly related to the intracellular imbalance between α- and β-like globin chains. Novel insights into the genetic modifiers have contributed to the understanding of the correlation between genotype and phenotype and are being explored as therapeutic pathways to cure this life-limiting disease. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Elsevier Health Science | en_US |
dc.subject | Gene regulation | en_US |
dc.title | Molecular basis and genetic modifiers of thalassemia | en_US |
dc.type | Review Article | en_US |
Appears in Collections: | Journal/Magazine Articles |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.